查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1973853

核子醫學測量設備市場：按技術、產品類型、應用和最終用戶分類－2026-2032年全球預測

Nuclear Medicine Instrumentation Market by Technology, Product Category, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，核醫測量設備市場價值將達到 45.1 億美元，到 2026 年將成長至 48.1 億美元，到 2032 年將達到 72.5 億美元，複合年成長率為 7.00%。

主要市場統計數據
基準年 2025 45.1億美元
預計年份：2026年 48.1億美元
預測年份 2032 72.5億美元
複合年成長率 (%) 7.00%

對影響全球醫療保健服務中診斷和治療創新的核醫設備進行全面調查。

過去十年，核醫儀器作為個人化診斷和治療路徑的基石，其重要性日益凸顯，徹底改變了臨床醫師檢測和治療複雜疾病的方式。隨著醫療服務提供者不斷追求更高的精準度和更好的患者療效，先進的影像技術和標靶放射性藥物遞送系統正處於醫學創新的前沿。這項變革得益於檢測器靈敏度、影像重建演算法以及影像與治療功能整合的突破性進展。因此，核子醫學如今在多學科醫學範式中佔據著至關重要的地位，為分子層面的生理過程提供了前所未有的深刻見解。

揭示驅動下一代核子醫學設備模式轉移：透過人工智慧分析、治療診斷學和精準影像診斷的整合

核醫儀器領域正因多種趨勢的整合而重塑，這些趨勢正在重新定義臨床工作流程和研究前沿。其中最顯著的是人工智慧 (AI) 和機器學習在影像擷取和解讀的應用。自動影像分割和前所未有的示踪劑擷取定量分析正在簡化決策流程，並減輕放射科醫生的工作量。同時，治療診斷一體化 (治療診斷學) 方法的蓬勃發展，使得分子影像劑兼具治療功能，為個人化醫療開闢了新的維度。如今，標靶放射性核種治療可由診斷回饋迴路即時指導，從而在確保更高療效的同時，最大限度地減少脫靶效應。

評估美國關稅對核醫設備供應鏈的連鎖反應：製造成本與全球合作。

2025年，美國新實施的關稅政策對整個核醫設備生態系統產生了多方面的連鎖反應。進口檢測器、CT模組和專用組件關稅的提高迫使製造商重新評估其全球供應鏈結構。為此，主要原始設備製造商（OEM）正在使其籌資策略多元化，並加快對本地組裝和組件製造的投資。雖然這些調整旨在抵消進口成本的增加，但考慮到放射性物質和成像設備嚴格的安全標準，這些調整也可能為品管和合規性帶來複雜性。

透過對核醫設備市場進行全面的技術產品類型、應用和最終用戶細分，得出策略性見解。

透過對技術採納、產品類型差異化、臨床應用和終端用戶專業知識的深入了解，我們得以揭示塑造當今核醫市場的複雜因素。包括PET/CT和SPECT/CT在內的混合影像平台的發展，凸顯了系統向無縫整合功能和解剖數據的轉變，從而滿足腫瘤分期和神經系統評估的嚴格要求。同時，診斷設備和治療設備之間界限的模糊化及其與放射性藥物的整合，凸顯了兩種戰略方向：一種側重於圖像採集和解讀，另一種側重於靶向放射性配體的給藥以達到治療目的。

為了解美洲、歐洲、中東和非洲以及亞太地區的區域趨勢，並闡明核子醫學影像的成長要素和擴散模式。

區域趨勢導致美洲、歐洲、中東和非洲以及亞太地區在技術採納率和創新軌跡方面存在差異。在美洲，完善的醫療基礎設施和充足的研究經費持續推動先進PET/CT和治療性診斷平台的早期應用。雖然北美醫療機構已廣泛採用整合成像療法，但拉丁美洲市場對攜帶式SPECT/CT解決方案的興趣日益濃厚，希望藉此擴大非都市區地區的診斷覆蓋範圍。

揭示核子醫學設備領域主要全球參與者的競爭領導地位和合作創新策略。

核醫學設備領域的主要企業正採取多元化策略，以保持競爭優勢並促進技術應用。全球巨頭企業不斷透過有針對性的收購和策略性研究合作來拓展產品系列，並將先進的檢測器技術和人工智慧軟體整合到現有平台中。同時，中型區域企業則專注於新興市場，致力於開發經濟高效的模組化系統和在地化服務模式，從而開拓專業化的細分市場。

為產業領導者制定可操作的藍圖，以最佳化技術投資、建立策略夥伴關係並改善患者治療效果。

為了掌握技術融合和監管變革帶來的機遇，產業領導者應優先投資於模組化、擴充性的平台，以滿足診斷成像和治療應用的需求。採用靈活的製造框架能夠幫助企業加速部署下一代檢測器和放射性藥物，同時降低供應鏈中斷的風險。組成跨職能團隊，涵蓋監管事務、臨床專家和資料科學家，能夠進一步簡化產品核可流程，並提升市場應對力。

為確保資料的完整性和可靠性，詳細闡述了嚴格的混合調查方法：將一手調查和二手調查與先進的分析技術結合。

本研究採用混合方法框架，結合了對臨床醫生、影像專家和採購經理的大量一手調查，以及涵蓋同行評審期刊、監管資料庫和專利申請的嚴謹二手調查。一手訪談和問卷調查直接提供了關於臨床工作流程、採購標準和新興需求的定性見解，而二手資訊來源提供了背景檢驗和趨勢分析。透過對這些資訊進行三角驗證，並進行交叉檢驗研討會以協調不同觀點並完善關鍵假設，從而確保了研究結果的穩健性。

本報告整合了關鍵研究成果，並提出了前瞻性的觀點，為相關人員提供有關核子醫學領域新興趨勢、機會和策略挑戰的指南。

這項綜合評估揭示了將決定核醫設備未來發展的關鍵技術創新、監管因素和競爭動態。從混合成像系統和人工智慧驅動的分析技術的興起，到治療性診斷模式的出現，相關人員都有機會釋放巨大的臨床和營運價值。供應鏈調整和區域差異化所帶來的成本進一步凸顯了敏捷策略規劃和穩健的夥伴關係生態系統的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：核子醫學測量設備市場：依技術分類

  • 混合成像
    • PET/CT系統
    • SPECT/CT系統
  • 正子斷層掃描
  • 單光子發射電腦斷層掃描

第9章：核醫測量設備市場（依產品類型）

  • 診斷設備
  • 醫療器材和放射性藥物

第10章 核子醫學測量設備市場：依應用領域分類

  • 心臟病學
  • 神經病學
  • 腫瘤學

第11章 核子醫學測量設備市場：依最終用戶分類

  • 診斷影像中心
  • 醫院
  • 研究機構

第12章 核子醫學測量設備市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 核子醫學測量設備市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 核子醫學測量設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國核子醫學測量設備市場

第16章：中國核子醫學測量設備市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AMETEK Inc.
  • BJ Madan & Co
  • Berthold Technologies GmbH & Co.KG
  • Blue Earth Diagnostics
  • Bruker Corporation
  • Canon Medical Systems Corporation
  • Cardinal Health
  • COMECER SpA
  • Digirad
  • Exosens
  • GE Healthcare
  • Geebee International
  • Hidex Oy
  • Jubilant DraxImage, Inc.
  • Koninklijke Philips NV
  • Mirion Technologies, Inc.
  • Neusoft Medical Systems Co., Ltd.
  • Nucleonix Systems（P）Ltd.
  • Nucleuz Healthcare Pvt Ltd
  • NUVIATech Healthcare
  • OVIS Imaging Solutions
  • Radiation Monitoring Devices
  • Rotem Industries Ltd.
  • Siemens Healthineers AG
  • Spectrum Instrumentation
Product Code: MRR-546E6FBB3C4B

The Nuclear Medicine Instrumentation Market was valued at USD 4.51 billion in 2025 and is projected to grow to USD 4.81 billion in 2026, with a CAGR of 7.00%, reaching USD 7.25 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.51 billion
Estimated Year [2026] USD 4.81 billion
Forecast Year [2032] USD 7.25 billion
CAGR (%) 7.00%

A Comprehensive Exploration of Nuclear Medicine Instrumentation Shaping Diagnostic and Therapeutic Innovations in Healthcare Delivery Worldwide

Over the past decade, nuclear medicine instrumentation has increasingly become a linchpin in personalized diagnostic and therapeutic pathways, revolutionizing how clinicians detect and treat complex diseases. As healthcare providers strive to enhance precision and patient outcomes, advanced imaging modalities and targeted radiopharmaceutical delivery systems have emerged at the forefront of medical innovation. This transformation has been driven by breakthroughs in detector sensitivity, image reconstruction algorithms, and the convergence of imaging with therapeutic functions. Consequently, nuclear medicine now occupies a pivotal position within multidisciplinary care paradigms, offering unparalleled insights into physiological processes at the molecular level.

Transitioning from conventional gamma cameras to sophisticated hybrid platforms, the field has undergone a profound metamorphosis. Hybrid imaging systems that combine positron emission tomography with computed tomography or single photon emission computed tomography with CT have enabled seamless integration of anatomical and functional data. These developments have not only sharpened diagnostic confidence but also expanded the scope of applications across cardiology, neurology, and oncology. Moreover, the ongoing miniaturization of components, along with enhancements in data processing and radiopharmaceutical chemistry, continues to lower operational barriers, facilitating broader adoption across hospitals, diagnostic centers, and research institutions. This report embarks on a comprehensive exploration of these technological advances, regulatory evolutions, and market dynamics, laying a solid foundation for the in-depth analysis that follows.

Unveiling the Paradigm Shifts Driving Next Generation Nuclear Medicine Instrumentation Through Integration of AI Analytics Theranostics and Precision Imaging

The landscape of nuclear medicine instrumentation has been reshaped by converging trends that are redefining clinical workflows and research frontiers. Foremost among these is the integration of artificial intelligence and machine learning into image acquisition and interpretation. By automating image segmentation and quantifying tracer uptake with unprecedented precision, these algorithms are streamlining decision-making and alleviating radiologist workloads. Simultaneously, the surge in theranostic approaches-where molecular imaging agents double as therapeutic vehicles-has introduced a new dimension of personalized medicine. Targeted radionuclide therapies are now guided in real time by diagnostic feedback loops, ensuring higher efficacy and minimizing off-target effects.

Additionally, the emphasis on hybrid imaging systems has fostered cross-disciplinary collaborations, uniting experts in radiopharmaceutical chemistry, nuclear physics, and bioengineering. This collective effort has given rise to next-generation detectors utilizing novel scintillating materials and semiconductor technology, thereby elevating spatial resolution and sensitivity. The growing need for point-of-care diagnostics has also spurred the development of compact, portable SPECT/CT and PET/CT systems, facilitating decentralized clinical trials and improving access in remote or community-based settings. Collectively, these transformative shifts underscore a trajectory toward faster, smarter, and more patient-centric nuclear medicine practices.

Assessing the Ripple Effects of United States Tariffs on Nuclear Medicine Instrumentation Supply Chains Manufacturing Costs and Global Collaboration

In 2025, newly enacted United States tariff policies have generated multifaceted ripple effects across the nuclear medicine instrumentation ecosystem. Heightened duties on imported detectors, CT modules, and specialized components have compelled manufacturers to reassess global supply chain architectures. In response, leading original equipment manufacturers are diversifying their sourcing strategies and accelerating investments in local assembly and component fabrication. While these adjustments aim to offset increased import costs, they also introduce complexities in quality control and regulatory compliance, given the stringent safety standards governing radioactive materials and imaging devices.

Consequently, distributors and end users are recalibrating procurement plans to accommodate extended lead times and restructured pricing models. Some institutions have turned to consortia agreements to leverage collective purchasing power and negotiate more favorable terms with suppliers. At the same time, research partners are exploring alternative detector chemistries and modular designs that can be adapted to regional manufacturing capabilities. Through these adaptive measures, stakeholders are striving to maintain uninterrupted clinical operations and uphold high standards of patient care. This section examines how the tariff environment is catalyzing innovation in production processes, spurring supply chain resilience, and redefining international collaboration within the nuclear medicine sector.

Strategic Insights Emerging from Comprehensive Technology Product Category Application and End User Segmentation in Nuclear Medicine Instrumentation Markets

Insights drawn from technology adoption, product category differentiation, clinical application, and end-user specialization reveal the intricate drivers shaping today's nuclear medicine market. The evolution of hybrid imaging platforms, including PET/CT and SPECT/CT modalities, underscores a shift toward systems that seamlessly integrate functional and anatomical data, satisfying the exacting requirements of oncological staging and neurological assessment. Simultaneously, the delineation between diagnostic instruments and therapeutic instruments coupled with radiopharmaceuticals highlights a dual-track strategy: one focused on image acquisition and interpretation, the other on delivering targeted radioligands for treatment.

Clinical fields such as cardiology, neurology, and oncology are each benefitting uniquely from these advancements, with oncology driving the largest volume of tracer development and neurology increasingly leveraging imaging biomarkers for neurodegenerative conditions. Moreover, the dispersal of capabilities across diagnostic imaging centers, hospitals, and research institutions reflects a broadening user base that demands scalable solutions. Diagnostic imaging centers prioritize throughput and cost efficiency, while hospitals emphasize integrated workflows within electronic health record systems. Meanwhile, research institutes underpin innovation pipelines, validating novel radiotracers and pilot-testing miniaturized instrumentation. These layered insights inform strategic positioning and product development roadmaps for stakeholders operating across the full spectrum of nuclear medicine instrumentation.

Understanding Regional Dynamics in the Americas Europe Middle East Africa and Asia Pacific to Uncover Growth Drivers and Adoption Patterns in Nuclear Imaging

Regional dynamics are driving divergent adoption rates and innovation trajectories across the Americas, Europe Middle East Africa region, and the Asia Pacific. In the Americas, established healthcare infrastructures and substantial research funding continue to foster early adoption of advanced PET/CT and theranostic platforms. North American centers are increasingly deploying integrated imaging therapies at scale, while Latin American markets demonstrate growing interest in portable SPECT/CT solutions to expand diagnostic access beyond urban hubs.

Across Europe, Middle East, and Africa, regulatory harmonization efforts and pan-regional research collaborations are enabling cross-border clinical trials and enhanced data sharing. Western European nations maintain leadership in radiopharmaceutical development, whereas emerging markets in the Gulf cooperation council countries and Southern Africa are investing in modernizing nuclear infrastructure. Meanwhile, the Asia Pacific region is characterized by rapid expansion driven by rising noncommunicable disease prevalence and robust government initiatives. Countries such as China, Japan, and India are scaling up local manufacturing capabilities and forging strategic alliances with global technology providers. These regional contrasts provide invaluable guidance for tailoring market entry approaches and aligning stakeholder investments with localized healthcare priorities.

Revealing Competitive Leadership and Collaborative Innovation Strategies Adopted by Key Global Participants in Nuclear Medicine Instrumentation

Leading participants in the nuclear medicine instrumentation sector are adopting multifaceted strategies to maintain competitive advantage and stimulate technology diffusion. Major global corporations continue to expand their product portfolios through targeted acquisitions and strategic research partnerships, embedding advanced detector technologies and AI-powered software into existing platforms. Concurrently, mid-sized regional players are carving out specialized niches by focusing on cost-effective modular systems and localized service models that cater to emerging markets.

Innovation alliances between imaging equipment manufacturers and radiopharmaceutical developers are accelerating integrated theranostic solutions, enabling coordinated roll-outs of diagnostic agents and companion therapies. Furthermore, joint ventures with academic institutions are enhancing R&D pipelines, particularly in developing novel tracers for neuroinflammation and receptor-targeted oncology. By balancing broad geographic reach with deep domain expertise, these organizations are cultivating resilient supply chains, reinforcing after-sales support networks, and driving sustained customer loyalty. The synthesis of these competitive and collaborative initiatives shapes a dynamic landscape where continuous innovation and partnership agility are paramount.

Formulating Practical Roadmaps for Industry Leaders to Optimize Technology Investments Forge Strategic Partnerships and Enhance Patient Outcomes

To harness the opportunities presented by technological convergence and regulatory evolution, industry leaders should prioritize strategic investments in modular, scalable platforms that accommodate both diagnostic imaging and therapeutic applications. By adopting flexible manufacturing frameworks, organizations can mitigate supply chain disruptions while accelerating deployment of next-generation detectors and radiopharmaceuticals. Establishing cross-functional teams that include regulatory affairs, clinical specialists, and data scientists can further streamline product approval timelines and enhance market responsiveness.

Collaboration with academic research centers and contract development organizations will be essential for fast-tracking the discovery and validation of novel tracers. Equally important is the cultivation of a comprehensive digital ecosystem, integrating advanced analytics and cloud-based image management to support remote interpretations and decentralized clinical trials. Building robust training programs for technologists and clinicians will drive effective technology utilization and foster stakeholder confidence. Ultimately, aligning these initiatives with patient-centered value propositions and health economic models will ensure that investments translate into measurable clinical benefits and sustainable growth trajectories.

Detailing Rigorous Mixed Methodology Combining Primary Engagement Secondary Research and Advanced Analytical Techniques to Ensure Data Integrity and Reliability

This research employs a mixed-methodology framework, combining extensive primary engagements with clinicians, imaging specialists, and procurement executives with rigorous secondary research across peer-reviewed journals, regulatory databases, and patent filings. Primary interviews and surveys yield firsthand qualitative insights into clinical workflows, purchasing criteria, and emerging needs, while secondary data sources provide contextual validation and trend analysis. Triangulation of these inputs ensures robustness, with cross-verification workshops conducted to reconcile divergent perspectives and refine key assumptions.

Quantitative analysis includes benchmarking component lifecycles, pricing variances, and throughput metrics, supported by statistical modeling to identify correlation patterns and technology adoption curves. A systematic review of regulatory pathways and reimbursement policies informs the risk assessment of market entry scenarios. Finally, iterative expert validation sessions with academic and industry advisory panels serve to stress-test the findings and calibrate strategic recommendations. This methodological rigor guarantees that the conclusions drawn are both actionable and reflective of real-world dynamics in the nuclear medicine instrumentation landscape.

Synthesizing Key Findings into Forward Looking Perspective Guiding Stakeholders on Emerging Trends Opportunities and Strategic Imperatives in Nuclear Medicine

This comprehensive assessment has illuminated the critical technological innovations, regulatory factors, and competitive dynamics that are defining the future of nuclear medicine instrumentation. From the ascendancy of hybrid imaging systems and AI-driven analytics to the emergence of theranostic paradigms, stakeholders are positioned to unlock significant clinical and operational value. Tariff-induced supply chain adaptations and regional differentiation further underscore the necessity for agile strategic planning and robust partnership ecosystems.

Looking ahead, the convergence of digital health platforms, precision radiopharmaceuticals, and decentralized diagnostic capabilities will continue to drive differentiation. Organizations that integrate cross-disciplinary expertise, prioritize patient-centric workflows, and commit to ongoing innovation will lead the next wave of growth. By synthesizing the insights presented herein, decision makers can confidently navigate emerging challenges, seize value creation opportunities, and advance the standard of care in nuclear medicine.

In summary, the trajectory of nuclear medicine instrumentation is characterized by rapid evolution and multifaceted opportunity. The strategic imperatives outlined in this report offer a clear roadmap for stakeholders seeking to translate cutting-edge science into tangible healthcare impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nuclear Medicine Instrumentation Market, by Technology

  • 8.1. Hybrid Imaging
    • 8.1.1. PET/CT Systems
    • 8.1.2. SPECT/CT Systems
  • 8.2. Positron Emission Tomography
  • 8.3. Single Photon Emission Computed Tomography

9. Nuclear Medicine Instrumentation Market, by Product Category

  • 9.1. Diagnostic Instruments
  • 9.2. Therapeutic Instruments & Radiopharmaceuticals

10. Nuclear Medicine Instrumentation Market, by Application

  • 10.1. Cardiology
  • 10.2. Neurology
  • 10.3. Oncology

11. Nuclear Medicine Instrumentation Market, by End User

  • 11.1. Diagnostic Imaging Centers
  • 11.2. Hospitals
  • 11.3. Research Institutes

12. Nuclear Medicine Instrumentation Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Nuclear Medicine Instrumentation Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Nuclear Medicine Instrumentation Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Nuclear Medicine Instrumentation Market

16. China Nuclear Medicine Instrumentation Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AMETEK Inc.
  • 17.6. B J Madan & Co
  • 17.7. Berthold Technologies GmbH & Co.KG
  • 17.8. Blue Earth Diagnostics
  • 17.9. Bruker Corporation
  • 17.10. Canon Medical Systems Corporation
  • 17.11. Cardinal Health
  • 17.12. COMECER SpA
  • 17.13. Digirad
  • 17.14. Exosens
  • 17.15. GE Healthcare
  • 17.16. Geebee International
  • 17.17. Hidex Oy
  • 17.18. Jubilant DraxImage, Inc.
  • 17.19. Koninklijke Philips N.V.
  • 17.20. Mirion Technologies, Inc.
  • 17.21. Neusoft Medical Systems Co., Ltd.
  • 17.22. Nucleonix Systems (P) Ltd.
  • 17.23. Nucleuz Healthcare Pvt Ltd
  • 17.24. NUVIATech Healthcare
  • 17.25. OVIS Imaging Solutions
  • 17.26. Radiation Monitoring Devices
  • 17.27. Rotem Industries Ltd.
  • 17.28. Siemens Healthineers AG
  • 17.29. Spectrum Instrumentation

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PET/CT SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PET/CT SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PET/CT SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY SPECT/CT SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY SPECT/CT SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY SPECT/CT SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY DIAGNOSTIC INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY DIAGNOSTIC INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY DIAGNOSTIC INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY THERAPEUTIC INSTRUMENTS & RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY THERAPEUTIC INSTRUMENTS & RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY THERAPEUTIC INSTRUMENTS & RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. GCC NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GCC NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. GCC NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 105. GCC NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. GCC NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. G7 NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. G7 NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. G7 NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 123. G7 NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 124. G7 NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. G7 NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. NATO NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. NATO NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. NATO NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 129. NATO NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. NATO NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA NUCLEAR MEDICINE INSTRUMENTATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)